Published in Blood on December 15, 2005
Efficient generation of human alloantigen-specific CD4+ regulatory T cells from naive precursors by CD40-activated B cells. Blood (2008) 1.64
Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PLoS One (2011) 1.38
CD40-activated B cells can be generated in high number and purity in cancer patients: analysis of immunogenicity and homing potential. Clin Exp Immunol (2008) 1.05
CD40 Ligand-activated, antigen-specific B cells are comparable to mature dendritic cells in presenting protein antigens and major histocompatibility complex class I- and class II-binding peptides. Immunology (2007) 0.99
Activated B cells modified by electroporation of multiple mRNAs encoding immune stimulatory molecules are comparable to mature dendritic cells in inducing in vitro antigen-specific T-cell responses. Immunology (2008) 0.87
CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells. Cancer Immunol Immunother (2012) 0.86
Potential impact of B cells on T cell function in multiple sclerosis. Mult Scler Int (2011) 0.85
Generation of human CD40-activated B cells. J Vis Exp (2009) 0.85
CD40-activated B cells can efficiently prime antigen-specific naïve CD8+ T cells to generate effector but not memory T cells. PLoS One (2012) 0.84
Fingolimod treatment promotes regulatory phenotype and function of B cells. Ann Clin Transl Neurol (2015) 0.84
Induction of protective cytotoxic T-cell responses by a B-cell-based cellular vaccine requires stable expression of antigen. Gene Ther (2009) 0.83
Design of CD40 agonists and their use in growing B cells for cancer immunotherapy. Int Rev Immunol (2012) 0.81
Therapeutic antitumor efficacy of B cells loaded with tumor-derived autophagasomes vaccine (DRibbles). J Immunother (2014) 0.80
The immunosuppressive factors IL-10, TGF-β, and VEGF do not affect the antigen-presenting function of CD40-activated B cells. J Exp Clin Cancer Res (2012) 0.80
Comparison of immunologic assays for detecting immune responses in HIV immunotherapeutic studies: AIDS Clinical Trials Group Trial A5181. Clin Vaccine Immunol (2010) 0.77
Murine model of CD40-activation of B cells. J Vis Exp (2010) 0.76
Detailed kinetics of the direct allo-response in human liver transplant recipients: new insights from an optimized assay. PLoS One (2010) 0.76
In vitro and in vivo imaging of initial B-T-cell interactions in the setting of B-cell based cancer immunotherapy. Oncoimmunology (2015) 0.76
MHC-Ig induces memory T cell formation in vivo and inhibits tumour growth. Immun Inflamm Dis (2014) 0.75
Efficient generation of antigen-specific CTLs by the BAFF-activated human B-lymphocytes as APCs: a novel approach for immunotherapy. Oncotarget (2016) 0.75
Combining dendritic cells and B cells for presentation of oxidised tumour antigens to CD8(+) T cells. Clin Transl Immunology (2017) 0.75
Dendritic cells and the control of immunity. Nature (1998) 56.54
Chemokines--chemotactic cytokines that mediate inflammation. N Engl J Med (1998) 12.80
CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell (1999) 12.50
Homing and cellular traffic in lymph nodes. Nat Rev Immunol (2003) 7.23
Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med (1998) 6.12
A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen. Cell (1996) 5.97
Chemokines and cell migration in secondary lymphoid organs. Science (1999) 5.18
A B-cell-homing chemokine made in lymphoid follicles activates Burkitt's lymphoma receptor-1. Nature (1998) 4.52
Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur J Immunol (1998) 4.51
Dendritic cells in the T-cell areas of lymphoid organs. Immunol Rev (1997) 4.41
Migratory properties of naive, effector, and memory CD8(+) T cells. J Exp Med (2001) 4.17
Antigen presentation by hapten-specific B lymphocytes. I. Role of surface immunoglobulin receptors. J Exp Med (1984) 3.36
Understanding dendritic cell and T-lymphocyte traffic through the analysis of chemokine receptor expression. Immunol Rev (2000) 3.18
Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med (1993) 3.04
Differential regulation of chemokine receptors during dendritic cell maturation: a model for their trafficking properties. J Immunol (1998) 2.70
Comparison of different isolation techniques prior gene expression profiling of blood derived cells: impact on physiological responses, on overall expression and the role of different cell types. Pharmacogenomics J (2004) 2.60
CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res (2003) 2.40
CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest (1997) 2.39
A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother (2001) 2.18
The CC chemokine receptor-7 ligands 6Ckine and macrophage inflammatory protein-3 beta are potent chemoattractants for in vitro- and in vivo-derived dendritic cells. J Immunol (1999) 1.73
Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res (1999) 1.73
RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. Blood (2003) 1.62
Differential responsiveness to constitutive vs. inducible chemokines of immature and mature mouse dendritic cells. J Leukoc Biol (1999) 1.50
Identification of novel CTL epitopes of CMV-pp65 presented by a variety of HLA alleles. Blood (2003) 1.25
Efficient generation of antigen-specific cytotoxic T cells using retrovirally transduced CD40-activated B cells. J Immunol (2002) 1.17
Maturation and trafficking of monocyte-derived dendritic cells in monkeys: implications for dendritic cell-based vaccines. J Immunol (2000) 1.12
Correspondence re R. Lapointe et al., CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res 2003;63:2836-43. Cancer Res (2004) 0.93
Gene therapy to target dendritic cells from blood to lymph nodes. Gene Ther (2003) 0.90
Regulatory T cells in cancer. Blood (2006) 3.56
Salicylic acid-independent ENHANCED DISEASE SUSCEPTIBILITY1 signaling in Arabidopsis immunity and cell death is regulated by the monooxygenase FMO1 and the Nudix hydrolase NUDT7. Plant Cell (2006) 2.87
Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood (2005) 2.81
Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells. J Exp Med (2004) 2.32
Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography. J Clin Oncol (2011) 2.10
Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. Blood (2007) 2.03
Intrahepatic IL-8 producing Foxp3⁺CD4⁺ regulatory T cells and fibrogenesis in chronic hepatitis C. J Hepatol (2013) 2.03
In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. Blood (2006) 1.92
Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood (2005) 1.89
FOXO-dependent regulation of innate immune homeostasis. Nature (2010) 1.89
Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol (2005) 1.78
Interim positron emission tomography scan in Hodgkin lymphoma: definitions, interpretation rules, and clinical validation. Leuk Lymphoma (2009) 1.66
Identification of an evolutionarily conserved transcriptional signature of CD8 memory differentiation that is shared by T and B cells. J Immunol (2008) 1.63
IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res (2011) 1.59
Indoleamine 2,3-dioxygenase-expressing dendritic cells form suppurative granulomas following Listeria monocytogenes infection. J Clin Invest (2006) 1.58
CD28 costimulation mediates down-regulation of p27kip1 and cell cycle progression by activation of the PI3K/PKB signaling pathway in primary human T cells. J Immunol (2002) 1.58
A highly standardized, robust, and cost-effective method for genome-wide transcriptome analysis of peripheral blood applicable to large-scale clinical trials. Genomics (2006) 1.51
Repression of the genome organizer SATB1 in regulatory T cells is required for suppressive function and inhibition of effector differentiation. Nat Immunol (2011) 1.49
Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res (2005) 1.48
A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254. Leuk Lymphoma (2011) 1.44
Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell. Clin Cancer Res (2007) 1.44
Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity. Blood (2005) 1.43
High-resolution transcriptome of human macrophages. PLoS One (2012) 1.42
Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res (2004) 1.42
Dendritic cells are significantly reduced in non-Hodgkin's lymphoma and express less CCR7 and CD62L. Leuk Lymphoma (2006) 1.39
Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells. Sci Transl Med (2011) 1.37
Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor. Cancer Res (2005) 1.32
Functional activity of natural antibody is altered in Cr2-deficient mice. J Immunol (2002) 1.29
miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia. Blood (2009) 1.25
Regulatory dendritic cells: there is more than just immune activation. Front Immunol (2012) 1.25
CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy. Cancer Res (2013) 1.22
Crosstalk between keratinocytes and adaptive immune cells in an IkappaBalpha protein-mediated inflammatory disease of the skin. Immunity (2007) 1.21
Global transcriptional profiles of beating clusters derived from human induced pluripotent stem cells and embryonic stem cells are highly similar. BMC Dev Biol (2010) 1.21
Keratin 1 maintains skin integrity and participates in an inflammatory network in skin through interleukin-18. J Cell Sci (2012) 1.18
IDO-expressing regulatory dendritic cells in cancer and chronic infection. J Mol Med (Berl) (2007) 1.18
Cancer-induced immunosuppression: IL-18-elicited immunoablative NK cells. Cancer Res (2012) 1.16
Prostaglandin E2 impairs CD4+ T cell activation by inhibition of lck: implications in Hodgkin's lymphoma. Cancer Res (2006) 1.15
Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proc Natl Acad Sci U S A (2003) 1.14
RNA fingerprints provide direct evidence for the inhibitory role of TGFbeta and PD-1 on CD4+ T cells in Hodgkin lymphoma. Blood (2007) 1.13
Immune modulation by zoledronic acid in human myeloma: an advantageous cross-talk between Vγ9Vδ2 T cells, αβ CD8+ T cells, regulatory T cells, and dendritic cells. J Immunol (2011) 1.13
O-Linked glycans control glycoprotein processing by antigen-presenting cells: a biochemical approach to the molecular aspects of MUC1 processing by dendritic cells. Eur J Immunol (2003) 1.12
CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans. Clin Cancer Res (2008) 1.11
Chimeric Antigen Receptor T Cells in Myeloma. N Engl J Med (2016) 1.11
Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies. Cancer Res (2010) 1.10
IL-7-dependent human leukemia T-cell line as a valuable tool for drug discovery in T-ALL. Blood (2003) 1.10
Blood-based gene expression signatures in non-small cell lung cancer. Clin Cancer Res (2011) 1.09
Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. Br J Haematol (2010) 1.09
Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: results of 2 phase 1 studies. Blood (2008) 1.07
Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer. Clin Cancer Res (2005) 1.06
Efficient presentation of naturally processed HLA class I peptides by artificial antigen-presenting cells for the generation of effective antitumor responses. Clin Cancer Res (2006) 1.06
Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission. J Clin Oncol (2012) 1.06
HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J Immunol (2002) 1.06
Autoantibodies frequently detected in patients with aplastic anemia. Blood (2003) 1.05
Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. Biol Blood Marrow Transplant (2007) 1.02
Regulatory T cells: major players in the tumor microenvironment. Curr Pharm Des (2009) 1.02
pH-triggered microparticles for peptide vaccination. J Immunol (2004) 1.00
Unique transcriptome signature of mouse microglia. Glia (2013) 1.00
cAMP inhibits both Ras and Rap1 activation in primary human T lymphocytes, but only Ras inhibition correlates with blockade of cell cycle progression. Blood (2002) 0.99
Constitutive expression of c-FLIP in Hodgkin and Reed-Sternberg cells. Am J Pathol (2002) 0.98
Bead array-based microrna expression profiling of peripheral blood and the impact of different RNA isolation approaches. J Mol Diagn (2010) 0.98
Statins inhibit human APC function: implications for the treatment of GVHD. Blood (2008) 0.98
Characterization of the BUD31 gene of Saccharomyces cerevisiae. Biochem Biophys Res Commun (2004) 0.98
Positioning of NORs and NOR-bearing chromosomes in relation to nucleoli. J Struct Biol (2007) 0.97
Common gamma chain-signaling cytokines promote proliferation of T-cell acute lymphoblastic leukemia. Haematologica (2004) 0.96
Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab. Am J Hematol (2002) 0.96
Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma. Br J Haematol (2003) 0.96
Blood-based transcriptomics: leukemias and beyond. Expert Rev Mol Diagn (2009) 0.95
Virally infected mouse liver endothelial cells trigger CD8+ T-cell immunity. Gastroenterology (2009) 0.95
Intrathecal rituximab treatment for pediatric post-transplant lymphoproliferative disorder of the central nervous system. Pediatr Blood Cancer (2008) 0.95
Dissociation of its opposing immunologic effects is critical for the optimization of antitumor CD8+ T-cell responses induced by interleukin 21. Clin Cancer Res (2008) 0.94
The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells. Blood (2003) 0.94
RNA stabilization of peripheral blood and profiling by bead chip analysis. Methods Mol Biol (2009) 0.94
An endohedral single-molecule magnet with long relaxation times: DySc2N@C80. J Am Chem Soc (2012) 0.93
Blockade of B7/CD28 in mixed lymphocyte reaction cultures results in the generation of alternatively activated macrophages, which suppress T-cell responses. Blood (2002) 0.93
Correspondence re R. Lapointe et al., CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res 2003;63:2836-43. Cancer Res (2004) 0.93